Production (Stage)
Century Therapeutics, Inc.
IPSC
$0.583
$0.00761.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.90M | 6.59M | 2.69M | 2.04M | 1.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.90M | 6.59M | 2.69M | 2.04M | 1.37M |
| Cost of Revenue | 110.40M | 107.24M | 100.17M | 95.73M | 91.23M |
| Gross Profit | 4.50M | -100.65M | -97.48M | -93.68M | -89.86M |
| SG&A Expenses | 34.18M | 34.51M | 33.99M | 34.62M | 34.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.58M | 141.76M | 134.16M | 130.35M | 125.78M |
| Operating Income | -29.68M | -135.17M | -131.47M | -128.31M | -124.41M |
| Income Before Tax | -20.16M | -124.78M | -130.75M | -131.64M | -132.80M |
| Income Tax Expenses | 1.79M | 1.79M | -854.00K | -254.00K | 674.00K |
| Earnings from Continuing Operations | -21.95 | -126.57 | -129.89 | -131.39 | -133.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.95M | -126.57M | -129.89M | -131.39M | -133.47M |
| EBIT | -29.68M | -135.17M | -131.47M | -128.31M | -124.41M |
| EBITDA | -16.38M | -121.86M | -117.93M | -114.72M | -111.05M |
| EPS Basic | -0.28 | -1.62 | -1.86 | -2.04 | -2.22 |
| Normalized Basic EPS | -0.14 | -0.98 | -1.03 | -1.10 | -1.16 |
| EPS Diluted | -0.28 | -1.62 | -1.86 | -2.04 | -2.22 |
| Normalized Diluted EPS | -0.14 | -0.98 | -1.03 | -1.10 | -1.16 |
| Average Basic Shares Outstanding | 338.23M | 314.51M | 289.09M | 263.83M | 240.99M |
| Average Diluted Shares Outstanding | 338.31M | 314.51M | 289.09M | 263.83M | 240.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |